Clinical and Radiographic Outcomes of Partial Pulpotomy Procedure in Primary Molars Utilizing Different Capping Materials and Different Restorative Methods

November 19, 2025 updated by: Ali Elsharkawy, British University In Egypt

Clinical and Radiographic Outcomes of Partial Pulpotomy Procedure in Primary Molars Utilizing Different Capping Materials and Different Restorative Methods: A Randomized Clinical Trial

the goal of this clinical trial is to compare clinical and radiographic outcomes of partial pulpotomy in vital primary molars using TheraCal PT®, Biodentin® and NeoPUTTY® MTA , followed by glass ionomer restoration only or glass ionomer restoration and stainless-steel crown.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

  • Primary teeth act as natural space maintainers for the subsequent dentition, they also aid in mastication, satisfactory esthetics and proper articulation of letters. So, it is of prime importance to maintain and preserve their vitality and function through vital pulp therapy (VPT). Ideal VPT materials would sustain pulp vitality, encourage pulp healing. Due to their biocompatibility, bioactivity, and superior sealing capacity, tricalcium silicates (TCSs), such as mineral trioxide aggregate (MTA) and Biodentine®, are currently the most widely used materials for VPT in permanent and primary teeth.Other calcium silicate-based compounds, such as TheraCal PT®, have recently been introduced to the market. TheraCal PT®, a dual-cured variation of its light-cured predecessor Theracal LC®, has improved its chemical capabilities to mitigate the potential harmful consequences of leaving un polymerized monomers.
  • The best course of action for primary molars with deep carious lesions that aren't exhibiting any symptoms or indicators of irreversible pulpitis has posed challenges for years. With pulp capping and pulpotomy available as options for primary teeth, and partial pulpotomy in young permanent teeth according to the American Academy of Pediatric Dentistry (AAPD) guidelines for vital pulp therapy. A less invasive version of pulpotomy which is partial pulpotomy uses more conservative theories and biologic principles to produce better clinical results
  • New iterations of calcium silicate-based materials have been created for usage as vital pulp therapy material due to their advantageous biological, physical, and mechanical qualities. Additionally, they promote growth factor production and differentiation into odontoblast like cells .
  • TheraCal PT® advantages include that it has a hydrophilic matrix which releases Calcium ions. Koutroulis et al.,stated that the increased antibacterial efficacy and calcium release are strongly linked. Also, Calcium release has been linked to the biological characteristics of hydraulic cements because it promotes the differentiation potential of dental pulp cells and enhances mineralization, which results in deposition of a dentine-like barrier on the pulp's surface on the long-term. The other advantage that it increases the pH which provides anti-bacterial activity.
  • there is lack of evidence in partial pulpotomy in treatment of carious primary teeth, the materials that could be used in it and necessity of using crown after it.
  • this clinical trial will be performed to provide evidence based answer for treatment of primary molars using partial pulpotomy the materials that could be used in it and necessity of using crown after it.

    -• Children will be allocated into either one of the groups of partial pulpotomy depending on the medicament used as follows:

    • Group 1A: (control group) MTA and stainless-steel crown.
    • Group 1B: MTA and glass ionomer restoration.
    • Group 2A: Biodentin® and stainless-steel crown.
    • Group 2B: Biodentin® and glass ionomer restoration.
    • Group 3A: TheraCal PT® and stainless-steel crown.
    • Group 3B: TheraCal PT® and glass ionomer restoration. All of the medicaments will be applied according to the manufacturer's instructions and gently placed over the pulp tissue to a thickness of 2mm then the rest of the pulp chamber will be filled with glass ionomer cement
  • Clinical follow up after 3,6,9 and12 months while radiographic follow up every 6 months.

    • Parents will be asked if any complains occurred between follow up visits by phone

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt
        • The british university in egypt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Healthy patients aged 4-7-years old.
  2. Cooperative patients (Frankle scale + and ++)
  3. Asymptomatic primary molar with deep caries requiring vital pulp therapy

Exclusion Criteria:

  • presence of any of the following:

    1. History of spontaneous lingering pain, swelling, or sinus tract.
    2. Pathological mobility.
    3. pain on percussion.
    4. Furcation or periapical radiolucency.
    5. pathological root resorption

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MTA and stainless-steel crown
2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
Experimental: Biodentine® and stainless-steel crown
2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
Experimental: TheraCal PT® and stainless-steel crown
2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
Experimental: MTA and glass ionomer restoration
2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
Experimental: Biodentine® and glass ionomer restoration
2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
Experimental: TheraCal PT® and glass ionomer
2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate and Compare clinical outcomes of TheraCal PT®, Biodentin® and NeoPUTTY®, followed by glass ionomer restoration only or glass ionomer restoration and stainless-steel crown.in partial pulpotomy in vital primary molars
Time Frame: 1 year
method of measurement: presence or absence of pain, swelling, fistula, mobility unit of measurement: yes or no
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate and compare Radiographic outcomes of TheraCal PT®, Biodentin® and NeoPUTTY® MTA, followed by glass ionomer restoration only or glass ionomer restoration and stainless-steel crown in partial pulpotomy in vital primary molars
Time Frame: 1year
method of measurement: comparing pre and post operative radiographs unit of measurement: presence of furcation or periapical radiolucency, pathologic external root resorption, or internal resorption
1year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2023

Primary Completion (Actual)

August 27, 2025

Study Completion (Actual)

August 31, 2025

Study Registration Dates

First Submitted

December 22, 2023

First Submitted That Met QC Criteria

January 25, 2024

First Posted (Actual)

January 26, 2024

Study Record Updates

Last Update Posted (Actual)

November 24, 2025

Last Update Submitted That Met QC Criteria

November 19, 2025

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 23-005

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulp Disease, Dental

Clinical Trials on partial pulpotomy

Subscribe